申请人:Purdue Pharma L.P.
公开号:US10030021B2
公开(公告)日:2018-07-24
In one aspect, the invention provides compounds of Formula I: (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, Y, Za are defined as set forth in the disclosure. The invention also provides compounds of any one of Formulae II to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.
在一个方面,本发明提供了式 I:(I)的化合物及其药学上可接受的盐和溶解物,其中 R1、R2、R3、R4、R5、Y、Za 的定义如公开内容所述。本发明还提供了式 II 至 VII、IA 至 IC 和 IIA 至 IIC 中任一项的化合物及其药学上可接受的盐和溶液。本发明的其它方面包括将式I至VII、IA至IC和IIA至IIC的化合物及其药学上可接受的盐和溶液用于治疗对一种或多种阿片受体的调节有反应的疾病。在某些实施方案中,本发明化合物可用于治疗疼痛。